

CITATION REPORT

List of articles citing

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study

DOI: 10.1016/s0140-6736(21)00238-5
Lancet, The, 2021, 397, 1075-1084.

Source: <https://exaly.com/paper-pdf/79788274/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
165	One-year sustained cellular and humoral immunities of COVID-19 convalescents. 2021 ,		14
164	Will the large-scale vaccination succeed in containing the COVID-19 pandemic and how soon?. 2021 ,		
163	Seroprevalence and Clinical Outcomes of SARS-CoV-2 in Paediatric Patients with Rheumatic Disease. <i>Rheumatology</i> , 2021 ,	3.9	0
162	Sustained neutralising antibodies in the Wuhan population suggest durable protection against SARS-CoV-2. <i>Lancet, The</i> , 2021 , 397, 1037-1039	4.0	1
161	The new SARS-CoV-2 variant and reinfection in the resurgence of COVID-19 outbreaks in Manaus, Brazil.		3
160	Covid-19: Eight in 10 Wuhan residents with antibodies had no symptoms, finds study. 2021 , 372, n778		
159	Will the Large-scale Vaccination Succeed in Containing the COVID-19 Epidemic and How Soon?.		
158	From first to second wave: follow-up of the prospective Covid-19 cohort (KoCo19) in Munich (Germany).		2
157	Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.		3
156	The immune response to the novel coronavirus infection. 2021 , 12, 33-40		1
155	Inferring the COVID-19 IFR with a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data.		3
154	Epidemiological characteristics and incubation period of SARS-CoV-2 during the 2020-2021 winter pandemic wave in north China: an observational study.		
153	Protective heterologous T cell immunity in COVID-19 induced by MMR and Tdap vaccine antigens. 2021 ,		2
152	Political Preferences, Knowledge, and Misinformation About COVID-19: The Case of Brazil. 3,		8
151	Review of Current COVID-19 Diagnostics and Opportunities for Further Development. 2021 , 8, 615099		27
150	Potent and Persistent Antibody Response in COVID-19 Recovered Patients. <i>Frontiers in Immunology</i> , 2021 , 12, 659041	8.4	2
149	The concordance between the evolutionary trend and the clinical manifestation of the two SARS-CoV-2 variants. 2021 , 8, nwab073		1

148	SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study. 2021 , 5,		0
147	SARS-CoV-2 RNA and antibody detection in human milk from a prospective multicenter study in Spain.		1
146	The landscape of COVID-19 vaccination among healthcare workers at the first round of COVID-19 vaccination in China: willingness, acceptance and self-reported adverse effects.		2
145	Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection. 2021 , 18, 1832-1834		9
144	Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset. <i>Frontiers in Immunology</i> , 2021 , 12, 708523	8.4	27
143	Quantifying the role of naturally- and vaccine-derived neutralizing antibodies as a correlate of protection against COVID-19 variants.		5
142	Advances in Neutralization Assays for SARS-CoV-2. 2021 , 94, e13088		10
141	Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent Covid-19 in a prospective multicentre cohort study.		1
140	Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan.		1
139	Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. 2021 , 19, 155		14
138	SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy. 2021 , 197, 111097		15
137	Examining Vaccine Hesitancy in Sub-Saharan Africa: A Survey of the Knowledge and Attitudes among Adults to Receive COVID-19 Vaccines in Ghana. <i>Vaccines</i> , 2021 , 9,	5.3	21
136	Status: nosocomial transmission and prevention of SARS-CoV-2 in a Danish context. 2021 , 129, 340-351		
135	kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive Health Care Workers. 2021 , 89, 97-103		14
134	Attitudes Toward COVID-19 Vaccines in Chinese Adolescents. 2021 , 8, 691079		5
133	Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2021 , 13,	6.2	4
132	Humoral immune durability of IgG for anti-SARS-CoV-2 in the normal pregnant women in Wuhan, China. 2021 , 69, 395-397		
131	Increase in SARS-CoV-2 seroprevalence in healthy blood donors after the second wave of COVID-19 pandemic in South-Eastern Italy: evidence for asymptomatic young individuals as potential virus spreaders.		

130	Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. <i>Nature Communications</i> , 2021 , 12, 4144	17.4	21
129	Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study. <i>Frontiers in Immunology</i> , 2021 , 12, 708184	8.4	5
128	Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity. <i>Frontiers in Immunology</i> , 2021 , 12, 722027	8.4	3
127	Epidemiological characteristics and incubation period of SARS-CoV-2 during the 2020-2021 winter pandemic wave in North China: An observational study. 2021 , 93, 6628-6633		2
126	Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager. 2021 , 39, 4921-4924		5
125	Dynamic Changes of Antibodies to SARS-CoV-2 in Close Contacts. 2021 , 14, 4233-4243		
124	SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain. 2021 ,		8
123	Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients. 2021 , 105, e226-e233		10
122	Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. 2021 , 14, 3459-3476		50
121	SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic. <i>Viruses</i> , 2021 , 13,	6.2	8
120	Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. <i>Nature Communications</i> , 2021 , 12, 4984	17.4	20
119	Prevalence and persistence of SARS-CoV2 antibodies among healthcare workers in Oman. 2021 , 14, 1578-1584		
118	Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1.		
117	SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021. 2021 , 36, 1236-1240		2
116	SARS-CoV-2's origin should be investigated worldwide for pandemic prevention. <i>Lancet, The</i> , 2021 , 398, 1299-1303	40	4
115	Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. 2021 , 11, 151		7
114	From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany). <i>BMC Infectious Diseases</i> , 2021 , 21, 925	4	3
113	Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens. 2021 , 2, 1050-1071.e7		10

112	Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. 2021 , 148, 1481-1492.e2	7
111	The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine. 2021 , 1	1
110	Estimated SARS-CoV-2 infection rate and fatality risk in Gauteng Province, South Africa: a population-based seroepidemiological survey. 2021 ,	8
109	Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study. 2021 , 19, 270	6
108	COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries. 2021 , 10, 122	16
107	Persistence and viability of SARS-CoV-2 in primary infection and reinfections. 2021 ,	1
106	Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. 2021 , 2021, 9822706	2
105	The landscape of COVID-19 vaccination among healthcare workers at the first round of COVID-19 vaccination in China: willingness, acceptance and self-reported adverse effects. 2021 , 1-11	4
104	Generation and persistence of S1 IgG and neutralizing antibodies in post-COVID-19 patients. 2021 , 50, 447	2
103	SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China. <i>Frontiers in Public Health</i> , 2021 , 9, 716483	6 0
102	Understanding the effectiveness of government interventions against the resurgence of COVID-19 in Europe. <i>Nature Communications</i> , 2021 , 12, 5820	17.4 22
101	Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors. 2021 , 232, 108871	1
100	Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects. 2021 , 101, 108215	4
99	PREVALENCE OF MARKERS OF SARS-COV-2 INFECTION AMONG RESIDENTS OF KYIV REGION AT THE BEGINNING OF THE COVID-19 EPIDEMIC [FIRST RESULTS IN UKRAINE. 2021 , 118-132	0
98	The way of SARS-CoV-2 vaccine development: success and challenges. 2021 , 6, 387	7
97	Inferring the COVID-19 infection fatality rate in the community-dwelling population: a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data. 1-29	2
96	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology.. 2022 , 42, 31-56	1
95	Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan, China. 2021 , 100181	5

94	SARS-CoV-2 Antibodies in Children: A One-Year Seroprevalence Study From June 2020 to May 2021 in Germany.		2
93	Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders. 2021 , 1-6		1
92	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities. 2021 , 12, 789374		0
91	Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France. 2021 , 1		1
90	A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021. 2021 ,		3
89	Immunocompromised children and young people are at no increased risk of severe COVID-19. 2021 ,		5
88	Better modelling of infectious diseases: lessons from covid-19 in China. 2021 , 375, n2365		1
87	Role of asymptomatic and pre-symptomatic infections in covid-19 pandemic. 2021 , 375, n2342		8
86	Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.. <i>EBioMedicine</i> , 2021 , 75, 103789	8.8	9
85	Two Cases of COVID-19 with Persistently Positive SARS-CoV-2-Specific IgM During One-Year Follow-Up - Sichuan Province, China, February 2021. 2021 , 3, 983-984		1
84	Awareness, attitude and practice during COVID-19 pandemic among non-health care Workers in a tertiary care hospital in South India: A cross sectional study.. 2021 , 1		
83	Preferred Quarantine Strategies Study for Inbound Travellers in the COVID-19 Vaccine Era.		
82	A Framework for Dominant Factors Revelation of the Outbreak Cause. 2021 ,		0
81	Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations.. 2022 , 11,		1
80	Single-Cell Analysis Reveals the Immune Characteristics of Myeloid Cells and Memory T Cells in Recovered COVID-19 Patients With Different Severities.. <i>Frontiers in Immunology</i> , 2021 , 12, 781432	8.4	1
79	Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.. <i>Frontiers in Immunology</i> , 2022 , 13, 829665	8.4	1
78	Prevalence of antibodies against SARS-CoV-2 among pregnant women in Norway during the period December 2019 through December 2020.. 2022 , 1-9		0
77	Patient and Clinical Factors at Admission Affect the Levels of Neutralizing Antibodies Six Months after Recovering from COVID-19.. <i>Viruses</i> , 2022 , 14,	6.2	1

76	Health Inequity and COVID-19. 2022 , 103-123		
75	Antibody Responses of the First Wave of Survivors infected with SARS-CoV-2 One Year Ago.. 2021 ,		
74	SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 - April 2021.. 2022 , 54, 81-86	17.4	1
73	Rapid biosensing SARS-CoV-2 antibodies in vaccinated healthy donors.. 2022 , 204, 114054		3
72	Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico.. <i>Nature Communications</i> , 2022 , 13, 589	17.4	3
71	Long term antibody response to SARS-CoV-2 in children.		
70	CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy.. 2022 , 1-10		
69	SARS-CoV-2 and COVID-19: revisiting the most important research questions.. 2021 , 11, 215		
68	The race for a COVID-19 vaccine: where are we up to?. 2021 , 1-22		2
67	Observed Protection Against SARS-CoV-2 Reinfection Following a Primary Infection: A Danish Cohort Study Using Two Years of Nationwide PCR-Test Data.		1
66	Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic. 2022 , 2, 66-88		3
65	Immunity post-COVID-19 recovery boosts the antibody immune response to SARS-CoV-2 vaccination.		
64	SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.. <i>Lancet Microbe, The</i> , 2022 ,	22.2	10
63	Why Controlling the Asymptomatic Infection Is Important: A Modelling Study with Stability and Sensitivity Analysis. <i>Fractal and Fractional</i> , 2022 , 6, 197	3	1
62	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant.. <i>ACS Infectious Diseases</i> , 2022 ,	5.5	0
61	Humoral Response and Safety of BNT162b2 mRNA Vaccine in Children with Rheumatic Diseases under Immunomodulatory Treatment: A Preliminary Study.. <i>Rheumatology</i> , 2022 ,	3.9	2
60	Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers.. <i>Vaccines</i> , 2022 , 10,	5.3	0
59	Long-term immune responses in patients with confirmed novel coronavirus disease-2019: a 9-month prospective cohort study in Shanghai, China.. <i>BMC Infectious Diseases</i> , 2022 , 22, 240	4	1

58	COVID-19 Clinical Presentation Among HIV-Infected Persons in China: A Systematic Review.. <i>Current HIV/AIDS Reports</i> , 2022 , 1	5.9	0
57	Factors affecting the content of Ig G-antibodies to S-protein SARS-CoV-2 in the blood of reconvalescents after new coronavirus infection (COVID-19). <i>Meditsinskiy Sovet</i> , 2022 , 51-65	0.4	1
56	The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study.. <i>Vaccines</i> , 2022 , 10,	5.3	0
55	Network Pharmacology Study to Elucidate the Key Targets of Underlying Antihistamines against COVID-19. <i>Current Issues in Molecular Biology</i> , 2022 , 44, 1597-1609	2.9	1
54	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.. <i>EBioMedicine</i> , 2022 , 79, 103986	8.8	3
53	Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up.. <i>Frontiers in Public Health</i> , 2021 , 9, 801609	6	1
52	Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV.. <i>Journal of Infectious Diseases</i> , 2021 ,	7	0
51	Prevalence of SARS-CoV-2 antibodies in hospital employees, Central Germany. <i>Laboratoriums Medizin</i> , 2022 , 46, 61-69		
50	STRUCTURAL AND PRACTICAL IDENTIFIABILITY ANALYSES ON THE TRANSMISSION DYNAMICS OF COVID-19 IN THE UNITED STATES. <i>Journal of Applied Analysis and Computation</i> , 2020 , 0-0	0.4	
49	The Short- and Long-Term Clinical, Radiological and Functional Consequences of COVID-19.. <i>Archivos De Bronconeumologia</i> , 2022 ,	0.7	0
48	Origin and Causes of Covid-19. <i>Economic and Financial Law & Policy - Shifting Insights & Values</i> , 2022 , 1-260.2		
47	State-wide random seroprevalence survey of SARS-CoV-2 past infection in a southern US State, 2020.. <i>PLoS ONE</i> , 2022 , 17, e0267322	3.7	
46	Analysis of COVID-19 Spread in Tokyo through an Agent-Based Model with Data Assimilation.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0
45	System analysis of the fast global coronavirus disease 2019 (COVID-19) spread. Can we avoid future pandemics under global climate change?. <i>Communicative and Integrative Biology</i> , 2022 , 15, 150-157	1.7	0
44	Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth CountyResults from a Population-Based Longitudinal Study in Germany. <i>Viruses</i> , 2022 , 14, 1168	6.2	0
43	Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021. <i>Nature Communications</i> , 2022 , 13,	17.4	1
42	Increased body mass index linked to decreased neutralizing antibody titers of inactivated SARS-CoV-2 vaccine in healthcare workers. <i>Obesity Science and Practice</i> ,	2.6	1
41	Immune Response to SARS-CoV-2 Vaccines. <i>Biomedicines</i> , 2022 , 10, 1464	4.8	2

40	Seroprevalence of SARS-CoV-2 in four states of Nigeria in October 2020: A population-based household survey. <i>PLOS Global Public Health</i> , 2022 , 2, e0000363		0
39	Comparison of the First and Second Wave of Infections by SARS-CoV-2: A Retrospective and Longitudinal Study From a Primary Health Care Center in Santiago of Chile. <i>Frontiers in Public Health</i> , 10,	6	0
38	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 13,	8.4	1
37	Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19. <i>Scientific Reports</i> , 2022 , 12,	4.9	0
36	COVID -19 and plasma cells: Is there long-lived protection?. <i>Immunological Reviews</i> ,	11.3	1
35	Two cases of acute respiratory failure following SARS-CoV -2 vaccination in post- COVID -19 pneumonia. <i>Respirology Case Reports</i> , 2022 , 10,	0.9	0
34	Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan. <i>Respiratory Research</i> , 2022 , 23,	7.3	0
33	Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. <i>Lancet Regional Health - Europe, The</i> , 2022 , 20, 100452		3
32	The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic. <i>Science</i> ,	33.3	20
31	Dynamic Behavior Investigation of a Novel Epidemic Model Based on COVID-19 Risk Area Categorization. <i>Fractal and Fractional</i> , 2022 , 6, 410	3	0
30	Temporal trends and differences of SARS-CoV-2-specific antibody responses in symptomatic and asymptomatic subjects: a longitudinal study from Umbria in Italy. <i>BMJ Open</i> , 2022 , 12, e056370	3	0
29	Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies. <i>Frontiers in Immunology</i> , 13,	8.4	0
28	Evaluating the impact of stay-at-home and quarantine measures on COVID-19 spread. 2022 , 22,		1
27	Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study.		0
26	Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.		0
25	How many asymptomatic cases were unconfirmed in the US COVID-19 pandemic? The evidence from a serological survey. 2022 , 164, 112630		0
24	The Proportion of Long-term Response to Anti-N Igg Antibody after 12 Months for COVID-19 Subclinical Infections and a Longitudinal Survey for COVID-19 Subclinical Infections in 2021. 2022 ,		0
23	Long-term outcomes in COVID-19 patients recovered from the first wave of the pandemic.		0

- 22 A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. ○
- 21 Long-Term Antibody Response to SARS-CoV-2 in Children. ○
- 20 Antimicrobial resistance of Staphylococcus spp isolated in dairy farms and its relationship with the antimicrobial control and treatment of bovine mastitis. ○
- 19 Exploring meteorological impacts based on Köppen-Geiger climate classification after reviewing China's response to COVID-19. **2022**, ○
- 18 SARS-CoV-2 seropositivity and HIV viral load among Mozambican pregnant women. **2022**, Publish Ahead of Print, ○
- 17 SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis. **2022**, 50, ○
- 16 Research on the Intelligent Design Countermeasures in the Post-COVID Era. **2022**, 391-412 ○
- 15 Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. ○
- 14 Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV). 1
- 13 A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to April 2022. ○
- 12 SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions. **2023**, 126, 155-163 ○
- 11 Analyzing the transmission of SVCV among zebrafish populations by compartment mathematical modeling. **2023**, 564, 739076 ○
- 10 Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population. **2022**, 19, 15257 ○
- 9 Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 or Post-Vaccination in Libyan Population: Comparison of Four Vaccines. **2022**, 10, 2002 ○
- 8 COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. **2022**, 8, ○
- 7 Humoral Response after Two Doses of BNT162b2 mRNA Vaccine Has a Role in Predicting Response after Three Doses That Is Related to Plasma HIV Viremia and Nadir CD4+ Cell Count in HIV-Positive Patients. **2023**, 11, 82 1
- 6 Cohort profile: A Québec-based plasma donor biobank to study COVID-19 immunity (PlasCoV). **2023**, 13, e068803 1
- 5 A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study. **2023**, 18, e0284046 ○

- 4 SARS-Cov-2 Infection and Seroconversion Rates in Healthcare Providers Prior to COVID-19 Vaccine Rollout. 109980042311616 ○
- 3 Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan. **2023**, ○
- 2 Efficacy and safety of COVID-19 vaccines for patients with spinal tumors receiving denosumab treatment: An initial real clinical experience study. 13, ○
- 1 Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic. **2023**, 18, e0269104 ○